Skip to content

Data Collection - Of Syncope Tilt Table Testing Study

Data Collection - Of Syncope Tilt Table Testing Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03721393
Acronym
COST3
Enrollment
50
Registered
2018-10-26
Start date
2019-10-04
Completion date
2023-05-08
Last updated
2023-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthostatic Hypotension, Reflex Syncope

Keywords

tilt table test, valsalva

Brief summary

To characterize the impact of orthostatic hypotension (OH) and reflex syncope on signals measured using a wearable cardiac monitor prototype device. To evaluate the relationship of signals measured from the wearable cardiac monitor prototype device with reported symptom severity of orthostatic intolerance per standard data collection, analysis, and questionnaires.

Detailed description

This is a non-randomized feasibility study that will enroll up to 50 participants that have undergone a previous autonomic reflect screen (ARS) assessment and were either diagnosed with OH or reflex syncope, or considered to be control subjects for this study. A maximum of 20 subjects diagnosed with reflex syncope, a maximum of 10 subjects diagnosed with OH and a maximum of 10 control subjects will be enrolled. There will be one study visit per subject.

Interventions

DEVICEWearable heart monitor

Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.

Sponsors

Boston Scientific Corporation
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing and capable to provide informed consent * Age 18 or above * No contraindications to undergo tilt table test, Valsalva maneuver test, and deep breathing test (Components of the ARS assessment) * Previously underwent a clinically indicated ARS assessment without complications (including deep breathing, Valsalva maneuver, and tilt table testing). Previously diagnosed with OH, reflex syncope, OR control subjects assessed as normal, based on the ARS assessment. Patient enrollment shall be based on the type of diagnosis. * Willing to participate in one additional tilt table test, Valsalva maneuver test, and deep breathing test (components of the ARS assessment)

Exclusion criteria

* Currently enrolled in another clinical trial that might interfere with data collection. * Subject is pregnant or planning to become pregnant during the study * Active Implantable Medical Device, e.g. cardiac implantable electronic devices, bladder stimulators, diaphragm stimulators, implantable neuro stimulator, implantable active monitoring devices, implantable active drug administration devices, etc. * Have a prosthetic cardiac valve or previously underwent cardiac valve surgery. * Known allergy to materials used in the study (adhesive, ECG electrodes) * Diagnosed with syncope due to cardiologic causes. * Have had a myocardial infarction in the previous 90 days * Have been diagnosed with tachycardia that requires medical treatment * Experienced complications during previous clinically indicated ARS assessment * Are on medications that could affect autonomic function, if considered not safe or unwilling to hold such medications for at least four half-lives prior to testing (judged by the study Principal Investigator) * Have any contraindication for tilt test, Valsalva maneuver test or deep breathing test

Design outcomes

Primary

MeasureTime frameDescription
Physiologic Signal Detection12 monthsCharacterize the impact of orthostatic hypotension (OH) and reflex syncope on physiologic signals measured using a wearable cardiac monitor prototype device.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026